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T
here is a general agreement that patients with COPD who are developing respiratory failure benefit from long-term oxygen therapy (LTOT) at home. 1, 2 When LTOT is started, the oxygen flow is individually adjusted to increase Pao 2 to Ͼ 60 mm Hg. 3, 4 Such a flow may be insufficient during sleep. We demonstrated earlier that some COPD patients undergoing LTOT desaturate during sleep despite breathing oxygen. 5 Fletcher et al 6 and Levi-Valensi et al 7 demonstrated that COPD patients with diurnal Pao 2 Ͼ 60 mm Hg while breathing air may also desaturate during sleep. Block et al 8 and Flenley 9 hypothesized that nocturnal hypoxemia may precip-itate development of cor pulmonale. Recent American Thoracic Society guidelines 4 for diagnosis and treatment of COPD recommended increasing oxygen flow by 1 L/min during sleep in patients undergoing LTOT to prevent nocturnal oxygen desaturation. However, those recommendations were not supported by any formal study demonstrating frequency of nocturnal desaturation in COPD patients breathing oxygen.
The aim of this study was to evaluate overnight oxygen saturation in a large nonselected group of COPD patients who were eligible for LTOT and were breathing oxygen at a flow assuring satisfactory oxygenation at rest and while awake (Pao 2 Ն 60 mm Hg; arterial oxygen saturation [Sao 2 ] Ͼ 90%).
Materials and Methods
We studied 82 consecutive COPD patients (54 men and 28 women; mean age, 60.2 Ϯ 8.2 years) who were eligible for LTOT. Diagnosis of COPD was established based on commonly accepted criteria. 3, 4 Indications for LTOT were stable hypoxemia, defined as (1) Pao 2 Ͻ 55 mm Hg, or (2) Pao 2 between 55 and 59 mm Hg if hypoxemia coexisted with one of the following signs: signs of pulmonary hypertension on chest radiograph (15 patients), signs of right ventricle hypertrophy on ECG (16 patients), or elevated (Ͼ 55%) hematocrit (10 patients). In all patients, spirometric and arterial blood gas measurements were performed in a steady state. Spirometry showed severe airway obstruction (mean FEV 1 , 0.87 Ϯ 0.33 L). The results of arterial blood gas measurements revealed hypoxemia (mean Pao 2 , 51.6 Ϯ 5 mm Hg) and hypercapnia (mean Paco 2 , 47.5 Ϯ 8.3 mm Hg). Details of patients' characteristics are shown in Table 1 .
Spirometry was performed using a dry spirometer (Vitalograph; Maidenhead, UK). Results are shown for body temperature and saturated pressure conditions. The normal values were those of the European Community of Coal and Steel. 10 Arterial blood gases were measured using microelectrodes (Corning 278 Blood Gas Analyzer; Corning; Medfield, MA).
Overnight pulse oximetry (PO) was performed twice. During the first night, patients breathed ambient air. During the second PO session, they breathed oxygen through nasal prongs at a flow ranging from 1 to 2.5 L/min, assuring good oxygenation at rest and while awake (Pao 2 Ն 60 mm Hg). The position of the nasal prongs was checked every hour by a nurse on duty, and on no occasion were prongs found out of place. PO was conducted between 10:00 pm and 6:00 am. We used two models of transcutaneous pulse oximeters: Pulsox 7 (Minolta; Osaka, Japan) and Biox 3700 (Ohmeda Monitoring Systems Group; Boulder, CO). Close attention was paid to proper fixation of the oxygen sensing device to a patient's finger to ensure stable recording. Both pulse oximeters have built-in memory allowing for Ն 8 h of oxygen saturation recording. To assure good-quality recording, the pulse oximeters were powered by an alternating-current electricity source. The software checked the Sao 2 signal. Artifacts such as an interruption of electricity supply or displacement of the measuring cell were recorded and influenced the quality index (Q). Q was considered an expression of the ratio of artifacts to effective recording time. The mean Q was 0.99 and 0.98, respectively, for the Pulsox 7 and Biox 3700 devices. Recorded data were analyzed using computer software (Proxan, version 1.0; M. Lagosz; Warsaw, Poland) as described elsewhere. 5 From multiple variables measured and calculated, we retained the following: mean overnight Sao 2 , minimum Sao 2 , the percentage of total recording time spent with pulse oximeter saturation of Ͻ 90% (T 90 ), the percentage of total recording time spent with saturation of Ͻ 85% (T 85 ), and Q. The protocol of the study was approved by the Ethics Committee of the Institute. All patients gave informed consent.
Statistical Analysis
Results of lung function tests and PO recordings were presented as mean value Ϯ SD. The unpaired Student's t test or Mann-Whitney rank sum test (when the t test failed) was used to compare results in two analyzed subgroups (SigmaStat, version 2.0; SPSS Inc; Chicago, IL).
Results
As expected, all patients desaturated during the night while breathing air, and the T 90 was 90% (Table 2) . While breathing oxygen, the mean overnight Sao 2 in the group as a whole was satisfactory (90.9 Ϯ 5.0%). However, we found that many patients spent an important part of the night in desaturation (Sao 2 Ͻ 90%). Using a cutoff point of a T 90 of Ͼ 30%, 7 we divided the study group into "nondesaturators" (43 subjects, 52.4%) and "desaturators" (39 subjects, 47.6%). Functional characteristics and results of both PO sessions in the two groups are shown in Table 3 . Typical PO tracings in one of the desaturators are shown in Figure 1 .
We tried to find relationships between daytime lung function variables and nocturnal desaturation. Table 3 for abbreviation.
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breathing oxygen predicted nocturnal desaturation in 18 of 22 patients who presented both signs (81.8%).
Discussion
We found that almost half of COPD patients eligible for LTOT desaturated during sleep despite breathing oxygen at an airflow ensuring good oxygenation at rest and while awake. To our best knowledge, our study is the first to assess the incidence of nocturnal desaturation in such a large nonselected group of COPD patients. Previous observations were based on much smaller groups.
As early as 1977, Flick and Block 11 first reported nocturnal desaturations in COPD patients receiving oxygen. Of 10 oxygen-breathing patients (2 L/min) who were all well oxygenated during the day (mean Sao 2 , 97 Ϯ 2%), 6 patients desaturated at night (mean Sao 2 , Ͻ 90%) despite oxygen supplementation.
Carroll et al 12 studied 10 COPD patients who had severe airway obstruction (mean FEV 1 , 0.53 L). They had been receiving oxygen at home for Ն 6 months. Their awake Pao 2 was Ͼ 8 kPa, and their Sao 2 was Ն 90% while breathing oxygen. Four patients demonstrated significant oxygen desaturation during sleep while breathing oxygen.
Ś liwiń ski et al 5 found important nocturnal desaturation in 19 out of 34 COPD patients receiving long-term oxygen supplementation. This phenomenon was more frequent in the "blue bloater" type of patients. Morrison et al 13 studied 11 COPD patients receiving LTOT (mean FEV 1 , 0.6 L; Pao 2 , 48 mm Hg; Paco 2 , 54 mm Hg) with satisfactory oxygenation while breathing oxygen (Pao 2 Ͼ 60 mm Hg). Three of these patients spent Ͻ 75% of the night with an Sao 2 of Ͼ 90% despite breathing oxygen. Servera et al 14 observed nocturnal desaturation in 5 of 34 COPD patients eligible for LTOT. A 0.5-L/min increase in oxygen flow abolished nocturnal desaturation.
The present study has one important limitation. Multiple arterial blood desaturations during sleep are a typical feature of obstructive sleep apnea syndrome (OSAS). 15 However, we made all possible efforts to exclude subjects with OSAS. All subjects who reported snoring were excluded. The history of nonsnoring was taken from bed partners and confirmed by the nurse on duty. Obese subjects (BMI Ͼ 30 kg/m 2 ) and subjects with a shirt-collar size of Ͼ 39 cm were also excluded. 16 All PO analog recordings were carefully checked. All episodes of desaturation below the initial saturation level were rather long (Fig 1) , with a gradual Sao 2 decrease over several minutes typical for COPD patients. 17 We did not find in any analog tracing the saw-tooth pattern of desaturations typical in patients with OSAS. We are confident that patients with OSAS were excluded from the analyzed material.
There are several mechanisms that may be responsible for nocturnal desaturations in patients with COPD. The minute ventilation decreases during sleep similarly in both normal subjects and COPD patients. The majority of desaturations appear during rapid eye movement sleep. Irregular breathing, especially shallow rapid breathing that increases physiologic dead space ventilation, and hypoventilation are responsible for that phenomenon. 18 The decreased activity of intercostal muscles and the increase of upper and lower airway resistance additionally decrease alveolar ventilation. Resetting of respiratory control to higher Paco 2 19 and lower Pao 2 20 during sleep also reduces ventilatory response to blood gas disorders.
The absence of a cough reflex during sleep in patients with disturbed mucociliary clearance increases the ventilation/perfusion imbalance due to mucus retention in the small airways. Hypoventilation and the increase of the ventilation/perfusion ratio results in transient hypoxemic episodes, mainly during rapid eye movement sleep. 17, 21, 22 The clinical importance of nocturnal desaturation in COPD patients is still under debate. Fletcher and coworkers 6,23-25 devoted a series of papers to this problem. They found that about 25% of COPD patients with daytime Pao 2 Ͼ 60 mm Hg experienced nocturnal desaturation. 6 Desaturators had higher pulmonary artery pressure (PAP) at rest and during exercise. 23 During a 3-year follow-up period, desaturators treated with oxygen during sleep showed a decrease in PAP, contrary to desaturating control patients in whom PAP increased 24 and who also had a shorter survival rate. 25 However, a paper by Chaouat et al 26 did not confirm that nocturnal desaturations in COPD patients with diurnal Pao 2 Ͼ 55 mm Hg resulted in a permanent increase of PAP.
Generally, it was found that the level of Pao 2 during the day correlates well with nocturnal desaturations. 27 However, there are large individual variations in nocturnal hypoxemia in COPD patients. Our data confirm that it is rather difficult to predict nocturnal desaturations from spirometric indexes and from the diurnal Pao 2 . The best predictor of nocturnal desaturation was diurnal Paco 2 . In the linear regression analysis, only Paco 2 correlated with T 90 while breathing oxygen (r ϭ Ϫ 0.43; p Ͻ 0.001).
Patients who significantly desaturate during sleep should have their oxygen flow increased during sleep. In hypercapnic patients, this may lead to in an increase in Paco 2 during sleep, up to dangerous levels. Servera et al 14 found that adding 0.5 L/min of oxygen flow in desaturators was sufficient to prevent nocturnal desaturation. Apparently, all those patients were hypercapnic during the day. The authors did not provide data on the arterial blood gases in the morning following nocturnal increase in oxygen flow.
In summary, around half of COPD patients undergoing LTOT experience nocturnal hypoxemia even though they are breathing oxygen at a flow that ensures satisfactory oxygenation during the day. The desaturation during sleep may be expected in patients with a Paco 2 of Ͼ 45 mm Hg and a Pao 2 of Ͻ 65 mm Hg while breathing oxygen. However, the "gold standard" for recognizing nocturnal desaturation remains overnight PO. We would suggest that PO be performed in all patients who are eligible for LTOT and present with hypercapnia.
